Literature DB >> 27344543

Variation in the management of ductal carcinoma in situ in the UK: Results of the Mammary Fold National Practice Survey.

.   

Abstract

INTRODUCTION: Ductal carcinoma in situ (DCIS) accounts for approximately 10% of all newly-diagnosed breast cancers in the UK. The latest national guidelines were published in 2009 and may not reflect current best practice. We aimed to explore variation in the current management of DCIS to support the need for updated guidelines.
METHODS: A national practice questionnaire was developed by the Mammary Fold Academic Committee (MFAC) focussing on the pre, intra and post-operative management of DCIS. Trainees at UK breast units were invited to complete the questionnaire at their multidisciplinary team meeting to provide a comprehensive picture of current national practice.
RESULTS: 76 of 144 UK breast units (52.8%) participated in the survey. Variation was observed in radiological pre-operative assessment with only 33/76 units (43.4%) performing routine ultrasound assessment of the tumour or axilla. There was no clear consensus regarding indications for mastectomy; multifocality (38.2%) and extensive microcalcifications (34.2%) were the most frequent indications. 34/76 units (44.7%) offered nipple sparing mastectomy. 33/76 units (43.3%) perform sentinel node biopsy in the presence of a palpable/mass lesion and 51/76 (67.1%) at the time of mastectomy. The most widely accepted pathological radial margin remained 2 mm (36.8%). The commonest factors in decision-making for radiotherapy were tumour grade (51.3%) and size (35.5%). Only 12 units (15.8%) routinely used the Van Nuys Prognostic Index. Approximately half of all breast units offer clinical long-term follow-up. DISCUSSION: There is marked variation in the management of DCIS in the UK. Updated evidence-based guidelines may standardise practice and improve outcomes for patients.
Copyright © 2016 Elsevier Ltd and British Association of Surgical Oncology/European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Ductal carcinoma in situ; Management; National practice; Survey

Mesh:

Substances:

Year:  2016        PMID: 27344543     DOI: 10.1016/j.ejso.2016.05.024

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  4 in total

1.  Surgeons' preferences for using sentinel lymph node biopsy in patients with ductal carcinoma in situ.

Authors:  Claudia J C Meurs; Janine A van Til; Marian B E Menke-Pluijmers; Stefanie de Vet; Sabine Siesling; Pieter J Westenend
Journal:  PLoS One       Date:  2022-06-06       Impact factor: 3.752

2.  The TeaM (Therapeutic Mammaplasty) study: Protocol for a prospective multi-centre cohort study to evaluate the practice and outcomes of therapeutic mammaplasty.

Authors:  Elizabeth Baker; Baek Kim; Tim Rattay; Kathryn Williams; Charlotte Ives; Dennis Remoundos; Chris Holcombe; Matthew D Gardiner; Abhilash Jain; Richard Sutton; Rajgopal Achuthan; Philip Turton; Patricia Fairbrother; Lisa Brock; Shweta Aggarwal; Naren Basu; John Murphy; Adam Trickey; R Douglas Macmillan; Shelley Potter
Journal:  Int J Surg Protoc       Date:  2016-09-14

3.  Assessment of the usefulness of prognostic Van Nuys Prognostic Index in the treatment in ductal carcinoma in situ in 15-year observation.

Authors:  Michał Kunkiel; Anna Niwińska
Journal:  Sci Rep       Date:  2021-11-22       Impact factor: 4.379

4.  National Variations in the Work-Up, Investigation, and Surgical Management of Ductal Carcinoma In Situ of the Breast across Canadian Surgeons.

Authors:  Ryerson Seguin; Lashan Peiris
Journal:  Curr Oncol       Date:  2021-03-29       Impact factor: 3.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.